Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Pharma Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure

Editor's pick
Bloomberg
9 June 2015
Hepatitis C treatment

Treatment For Welsh Hepatitis C Patients With Advanced Liver Disease

Editor's pick
Swansea Sound
8 June 2015
Access to healthcare

Patients Get Extreme to Obtain Hepatitis Drug That's 1% the Cost Outside U.S.

Editor's pick
Bloomberg
2 June 2015
Drug interactions & pharmacokinetics

Almost Three Quarters of HIV/HCV Group May Have DDA-ARV Interactions

Editor's pick
NATAP
2 June 2015
Pharmaceutical industry

Panel: Compulsory licensing could address high-priced medicines in Europe

Editor's pick
Intellectual Property Watch
29 May 2015
Access to healthcare

Consumers Sue Anthem for Denying Coverage for a Hepatitis C Drug

Editor's pick
Wall Street Journal
28 May 2015
Finance & funding

NHS England accused of interference over hepatitis C drug

Editor's pick
Channel 4 News
26 May 2015
Hepatitis C treatment

Hepatitis B and C - An Action Plan for Saving Lives in Europe

Editor's pick
European Liver Patients Association
20 May 2015
Hepatitis C treatment

Pricing remains main barrier to HCV eradication

Editor's pick
Digestive Disease Week News
20 May 2015
Pharmaceutical industry

Is Gilead Sciences Its Own Worst Enemy?

Editor's pick
Motley Fool
20 May 2015
Hepatitis C treatment

Investing in hepatitis C drugs could save the economy billions, researchers suggest

Editor's pick
Medical News Today
19 May 2015
Hepatitis C treatment

The VA's Hepatitis C Problem

Editor's pick
Newsweek
14 May 2015
Hepatitis C treatment

Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs

Editor's pick
Wall Street Journal (blog)
13 May 2015
Access to healthcare

WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers

Editor's pick
World Health Organization
11 May 2015
Access to healthcare

Gilead: Stop Blocking Access to Hepatitis C Treatment

Editor's pick
Treatment Action Group
5 May 2015
Access to healthcare

Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

Editor's pick
Hep C Coalition
5 May 2015
Hepatitis C treatment

Egypt opens first factory for locally produced Sovaldi

Editor's pick
News Egypt
5 May 2015
Pharmaceutical industry

Gilead first-quarter profit doubles on strong hepatitis C drug sales

Editor's pick
Reuters
5 May 2015
Hepatitis C treatment

EASL Recommendations on Treatment of Hepatitis C 2015

Editor's pick
EASL
23 April 2015
Hepatitis C transmission & prevention

Gilead uses Georgia as free-drug testbed for hepatitis C elimination

Editor's pick
Reuters
23 April 2015
Hepatitis C treatment

Report: Hepatitis C in Eastern Europe and Central Asia: Epidemic and Response

Editor's pick
EATG
23 April 2015
Hepatitis C treatment

Union of South American Nations (UNASUR) proposes centralised purchase of hepatitis C treatments Olysio and Sovaldi for member states

Editor's pick
IHS
21 April 2015
Hepatitis C treatment

Is There Any Good Reason Left to Delay Hepatitis C Treatment?

Editor's pick
Poz
17 April 2015
Hepatitis C treatment

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Editor's pick
The Street
9 April 2015